AWS will help Amgen discover, develop, and boost the production throughput of medicines and increase sustainability and operational efficiency at the latter’s new facility for advanced medicine assembly
An image of Amgen’s office. (Credit: Amgen Inc.)
Amazon Web Services (AWS), an Amazon company, has joined forces with Amgen to create generative artificial intelligence (generative AI)-based solutions to accelerate the development of advanced therapies.
AWS will help Amgen discover, develop, and boost the production throughput of medicines for patients suffering from serious diseases.
Additionally, the American biopharmaceutical company will leverage AWS’s advanced services and global infrastructure to power its new digital data and analytics platform.
According to Amazon, the partnership will boost sustainability and operational efficiency at Amgen’s new facility for advanced medicine assembly and final product packaging.
The site is expected to open in the greater Columbus, Ohio, area early next year.
It will incorporate a connected digital platform on AWS using Amazon SageMaker, a fully managed service for creating, honing, and deploying machine learning (ML) models, to gather and analyse manufacturing data points daily.
The platform will use AI, sensors, and machine vision systems in the packing lines to help decrease operator intervention and increase the ergonomic safety of manual labour, Amazon said.
Furthermore, ML models will be combined with the gathering and reporting of real-time performance indicators to anticipate and stop equipment failure before it occurs.
Amgen senior vice president and chief information officer Mike Zahigian said: “Beyond optimising clinical trials and regulatory filings, we’re excited about making generative AI assistance available to our scientists, researchers, engineers, and others among our workforce.
“Our work with AWS over the last 10 years has helped us reinforce our data-driven approach, and working closely with AWS experts in machine learning and analytics allows us to move forward at an accelerated pace.”
Together, both firms are experimenting with generative AI and ML technologies to create solutions for various R&D needs like clinical trials.
The firms are also investigating solutions for operations and commercial lines of business using Amazon Bedrock and Amazon SageMaker JumpStart.
AWS technology VP Matt Wood said: “Our life sciences customers are looking to the potential of generative AI to help accelerate innovation and increase efficiencies across the care continuum.
“Combining AWS’s expansive capabilities and our 25 years of machine learning expertise with Amgen’s life sciences leadership and innovative culture, we are proud to work together to transform new ideas and discoveries into medicines that will improve treatment for patients with serious illnesses.”